These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36070939)

  • 61. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures.
    Gutman JM; Kupersmith M; Galetta S; Kister I
    J Neurol Sci; 2018 Apr; 387():170-173. PubMed ID: 29571858
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.
    Juryńczyk M; Jacob A; Fujihara K; Palace J
    Pract Neurol; 2019 Jun; 19(3):187-195. PubMed ID: 30530724
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anti-MOG-associated demyelinating disorders: two sides of the same coin.
    Maniscalco GT; Allegorico L; Alfieri G; Napolitano M; Ranieri A; Renna R; Servillo G; Pezzella M; Capone E; Altomare L; Spiniello M; Ferrari S; Manzo V; Mariotto S
    Neurol Sci; 2021 Apr; 42(4):1531-1534. PubMed ID: 33190197
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Diagnostic value of antibodies to myelin oligodendrocyte glycoprotein in demyelinating diseases of the central nervous system].
    Shchepareva ME; Kochergin IA; Tolpeeva OA; Shabalina AA; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):18-23. PubMed ID: 31156236
    [TBL] [Abstract][Full Text] [Related]  

  • 65. MOG-Ab titer-guided approach for steroid tapering to prevent relapse in children with mog antibody-associated adem diseases: A case report.
    Kurane K; Monden Y; Tanaka D; Gunji Y; Ikeda T; Miyauchi A; Osaka H; Takahashi T; Yamagata T
    Mult Scler Relat Disord; 2020 Oct; 45():102320. PubMed ID: 32622298
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein.
    Spadaro M; Winklmeier S; Beltrán E; Macrini C; Höftberger R; Schuh E; Thaler FS; Gerdes LA; Laurent S; Gerhards R; Brändle S; Dornmair K; Breithaupt C; Krumbholz M; Moser M; Krishnamoorthy G; Kamp F; Jenne D; Hohlfeld R; Kümpfel T; Lassmann H; Kawakami N; Meinl E
    Ann Neurol; 2018 Aug; 84(2):315-328. PubMed ID: 30014603
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.
    Reindl M; Linington C; Brehm U; Egg R; Dilitz E; Deisenhammer F; Poewe W; Berger T
    Brain; 1999 Nov; 122 ( Pt 11)():2047-56. PubMed ID: 10545390
    [TBL] [Abstract][Full Text] [Related]  

  • 68. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
    Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M
    Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Persistent presence of the anti-myelin oligodendrocyte glycoprotein autoantibody in a pediatric case of acute disseminated encephalomyelitis followed by optic neuritis.
    Miyauchi A; Monden Y; Watanabe M; Sugie H; Morita M; Kezuka T; Momoi M; Yamagata T
    Neuropediatrics; 2014 Jun; 45(3):196-9. PubMed ID: 24610298
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report.
    Nakamura Y; Nakajima H; Tani H; Hosokawa T; Ishida S; Kimura F; Kaneko K; Takahashi T; Nakashima I
    BMC Neurol; 2017 Apr; 17(1):76. PubMed ID: 28420330
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients.
    Zhao Y; Tan S; Chan TCY; Xu Q; Zhao J; Teng D; Fu H; Wei S
    Br J Ophthalmol; 2018 Oct; 102(10):1372-1377. PubMed ID: 29363529
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.
    Zhou D; Srivastava R; Nessler S; Grummel V; Sommer N; Brück W; Hartung HP; Stadelmann C; Hemmer B
    Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19057-62. PubMed ID: 17142321
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multiple intracranial lesions with lung adenocarcinoma: A rare case of MOG-IgG-associated encephalomyelitis.
    Li K; Zhan Y; Shen X
    Mult Scler Relat Disord; 2020 Jul; 42():102064. PubMed ID: 32234600
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations.
    Pittock SJ; Reindl M; Achenbach S; Berger T; Bruck W; Konig F; Morales Y; Lassmann H; Bryant S; Moore SB; Keegan BM; Lucchinetti CF
    Mult Scler; 2007 Jan; 13(1):7-16. PubMed ID: 17294606
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: A multicenter study in South China.
    Chen L; Chen C; Zhong X; Sun X; Zhu H; Li X; Yang H; Shu Y; Chang Y; Hu X; Lu Z; Peng L; Qiu W
    J Neuroimmunol; 2018 Aug; 321():83-91. PubMed ID: 29957392
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.
    Durozard P; Rico A; Boutiere C; Maarouf A; Lacroix R; Cointe S; Fritz S; Brunet C; Pelletier J; Marignier R; Audoin B
    Ann Neurol; 2020 Feb; 87(2):256-266. PubMed ID: 31725931
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [A patient with anti-myelin oligodendrocyte glycoprotein antibody-associated combined central and peripheral demyelination with anti-galactocerebroside and anti-GM1 antibodies].
    Fuse K; Araki A; Morozumi S; Yasui K
    Rinsho Shinkeigaku; 2023 Jul; 63(7):461-466. PubMed ID: 37394490
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 79. B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination.
    Kothur K; Wienholt L; Tantsis EM; Earl J; Bandodkar S; Prelog K; Tea F; Ramanathan S; Brilot F; Dale RC
    PLoS One; 2016; 11(2):e0149411. PubMed ID: 26919719
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.
    Sepúlveda M; Armangue T; Martinez-Hernandez E; Arrambide G; Sola-Valls N; Sabater L; Téllez N; Midaglia L; Ariño H; Peschl P; Reindl M; Rovira A; Montalban X; Blanco Y; Dalmau J; Graus F; Saiz A
    J Neurol; 2016 Jul; 263(7):1349-60. PubMed ID: 27147513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.